Herpesvirus latency and symbiotic protection from bacterial infection

Viral Immunology

Volumn 22, Issue 1, 2009, Pages 3-4

  Barton, Erik S ^a   White, Douglas W ^a   Virgin, Herbert W ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

HERPES VACCINE; LIVE VACCINE; MEASLES VACCINE; VARICELLA ZOSTER VACCINE; VIRUS DNA;

BACTERIAL INFECTION; CD8+ T LYMPHOCYTE; CYTOMEGALOVIRUS; DISEASE ASSOCIATION; DISEASE SEVERITY; DNA DETERMINATION; EPSTEIN BARR VIRUS; GAMMAHERPESVIRUS 68; HERPES VIRUS; HERPES VIRUS INFECTION; HUMAN; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 7; IMMUNE SYSTEM; IMMUNITY; IMMUNOCOMPROMISED PATIENT; INFECTION PREVENTION; LETTER; LISTERIA MONOCYTOGENES; MEASLES; MEASLES VIRUS; NONHUMAN; SECONDARY INFECTION; SYMBIOSIS; VACCINE PRODUCTION; VARICELLA ZOSTER VIRUS; VIRUS LATENCY; VIRUS REACTIVATION;

ANIMALS; GAMMAHERPESVIRINAE; HERPESVIRIDAE INFECTIONS; HUMANS; LISTERIA INFECTIONS; LISTERIA MONOCYTOGENES; MICE; MICE, INBRED C57BL; SYMBIOSIS; VIRUS LATENCY;

BACTERIA (MICROORGANISMS); HERPESVIRIDAE;

EID: 60149106727     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2008.0100     Document Type: Letter

References (15)

1. Balthesen M, Messerle M, and Reddehase MJ: Lungs are a major organ site of cytomegalovirus latency and recurrence. J Virol 1993;67:5360-5366.
2. Barton ES, White DW, Cathelyn JS, et al.: Herpesvirus latency confers symbiotic protection from bacterial infection. Nature 2007;447:326-329.
3. Felsenstein J, Horino H, Lamont S, et al.: PopG v3.3. A onelocus, two-allele genetic simulation program. University of Washington. Simulation assumptions: 100 populations of 10,000 ancestral vertebrates experiencing frequent inter-population migration (0.5); latent infection as a dominant allele with a prior frequency of 1e-5 conferring a selective advantage of one percent relative to non-latently-infected hosts, 2008.
4. Haine ER: Symbiont-mediated protection. Proc R Soc B: Biol Sci 2008;275:353-361.
5. Haque A, Rachinel N, Quddus MR, Haque S, Kasper LH, and Usherwood E: Co-infection of malaria and gamma-herpesvirus: exacerbated lung inflammation or cross-protection depends on the stage of viral infection. Clin Exp Immunol 2004;138:396-404.
6. + T cells and the virus-host balance. J Clin Invest 2005;115:2546-2555.
7. Moss WJ, Ota MO, and Griffin DE: Measles: immune suppression and immune responses. Int J Biochem Cell Biol 2004;36:1380-1385.
8. Nguyen YN, McGuffie BA, Anderson VE, and Weinberg JB: Gammaherpesvirus modulation of mouse adenovirus type 1 pathogenesis. Virology 2008;380:182-190.
9. Reddehase MJ, Balthesen M, Rapp M, Jonjic S, Pavic I, and Koszinowski UH: The conditions of primary infection define the load of latent viral genome in organs and the risk of recurrent cytomegalovirus disease. J Exp Med 1994;179:185-193.
10. Rickinson AB, and Kieff E: Epstein-Barr virus. In: Fields Virology. (Knipe DM, and Howley PM, eds.). Lippincott Williams & Wilkins, Baltimore, 2001, pp. 2575-2628.
11. Schaub B, Lauener R, and von Mutius E: The many faces of the hygiene hypothesis. J Allergy Clin Immunol 2006;117:969-977; quiz 978.
12. Steffens H.-P., Kurz S, Holtappels R, and Reddehase MJ: Preemptive CD8 T-cell immunotherapy of acute cytomegalovirus infection prevents lethal disease, limits the burden of latent viral genomes, and reduces the risk of virus recurrence. J Virol 1998;72:1797-1804.
13. Tibbetts SA, Loh J, Van Berkel V, et al.: Establishment and maintenance of gammaherpesvirus latency are independent of infective dose and route of infection. J Virol 2003;77:7696-7701.
14. Willer DO, and Speck SH: Long-term latent murine gamma-herpesvirus 68 infection is preferentially found within the surface immunoglobulin D-negative subset of splenic B cells in vivo. J Virol 2003;77:8310-8321.
15. Yager EJ, Szaba FM, Kummer LW, Lanzer KG, Burkum CE, Smiley ST, and Blackman MA: γ-Herpesvirus-induced protection against bacterial infection is transient. Viral Immunol 2009 (in press).